Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Antonelli Luca, Wendel-Garcia Pedro David, Deforth Manja, Afferi Luca, Leonardo Costantino, Esperto Francesco, Borghesi Marco, Antonelli Alessandro, Tully Karl, Umari Paolo, Albisinni Simone, Mari Andrea, Pichler Renate, Claps Francesco, Teoh Jeremy Yuen-Chun, Roumiguié Mathieu, Schulz Gerald Bastian, Orecchia Luca, Soria Francesco, Roupret Morgan, Marcq Gautier, Poyet Cedric, Alrumayyan Majed, Rink Michael, Zamboni Stefania, Montes Maria Riaza, Okoye Steven, Campi Riccardo, Krajewski Wojciech, Mertens Laura, Culpan Meftun, Lavallée Luke T, Moschini Marco, Held Ulrike, Fankhauser Christian Daniel, EAU YAU urothelial carcinoma working group
Аннотация
MATERIALS AND METHODS: We conducted a retrospective cohort study in 4886 patients with non-metastatic bladder cancer undergoing cystectomy across 28 centres in 13 countries between 1990 and 2021. Inverse probability weighting analyses were performed to estimate the effect of thromboprophylaxis on VTE and bleeding.
RESULTS: In 147 patients (3%) VTEs were recorded within the first year. These occurred a median (interquartile range [IQR]) of 127 (82-198) days after bladder cancer diagnosis. Bleeding events occurred in 131 patients (3%) within the first year. These occurred a median (IQR) of 101 (83-171) days after cancer diagnosis. In inverse probability weighting analyses, compared to patients without thromboprophylaxis during chemotherapy, patients with thromboprophylaxis had not only a lower risk of VTE (hazard ratio [HR] 0.32, 95% confidence interval [CI] 0.12-0.81; P = 0.016) but also a lower bleeding risk (HR 0.03, 95% CI 0.09-0.12; P <0.0001). The retrospective nature of the study was its main limitation.
CONCLUSIONS: In this retrospective analysis, the benefit of thromboprophylaxis during neoadjuvant chemotherapy before cystectomy is in line with data from randomised trials in other malignancies. Our data suggest thromboprophylaxis is protective against VTEs and should be the standard of care during neoadjuvant chemotherapy.